Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

41. Systematic review and meta-analysis: Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target

Systematic review and meta-analysis: Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target Article Text Therapeutics Systematic review and meta-analysis Long-term antibiotic

Evidence-Based Medicine (Requires free registration)2014

42. 2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of COPD

2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of COPD ONLINE FIRST This is an Online First, unedited version of this article. The final, edited version will appear in a numbered issue of CHEST and may contain substantive changes. We encourage readers to check back for the final article. Online First papers are indexed in PubMed and by search engines, but the information, including the final title and author list, may be updated on final publication. http (...) ://journal.publications.chestnet.org/ Online First articles are not copyedited prior to posting. ©American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. Page 1 of 28 Downloaded From: http://journal.publications.chestnet.org/ on 10/23/2014 1 Word Count: 6742 Executive Summary Prevention of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: American College of Chest Physicians and Canadian

Canadian Thoracic Society2014

43. Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD: The EPOC en Servicios de Medicina Interna (ESMI) Study

Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD: The EPOC en Servicios de Medicina Interna (ESMI) Study 23303399 2013 01 10 2013 02 11 2015 11 19 1931-3543 142 5 2012 Nov Chest Chest Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. 1126-33 10.1378/chest.11-2413 Comorbidities are frequent in patients hospitalized for COPD exacerbation, but little (...) is known about their relation with short-term mortality and hospital readmissions. Our hypothesis is that the frequency and type of comorbidities impair the prognosis within 12 weeks after discharge. A longitudinal, observational, multicenter study of patients hospitalized for a COPD exacerbation with spirometric confirmation was performed. Comorbidity information was collected using the Charlson index and a questionnaire that included other common conditions not included in this index. Dyspnea

EvidenceUpdates2013

44. Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy

Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute Exacerbations with Supplementation to Baseline Therapy "Herbal Therapy and Stable COPD: Delaying Onset and Duration of Acute E" by Amy M. Hernandez < > > > > > Title Author Date of Award Fall 10-18-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Patients with chronic obstructive pulmonary disease (COPD) experience progressive pulmonary decline (...) with each acute exacerbation of disease. Current therapy is focused on treating acute symptoms of COPD, but there are no medications that have been implemented to delay the progression of the disease. Herbal therapies have been developed by researchers to supplement baseline therapy for COPD with the goal of prolonging healthful pulmonary states, thereby slowing disease progression. Methods: Exhaustive search of available medical literature from Medline, CINAHL, Web of Science, EBMR and NIH websites

Pacific University EBM Capstone Project2013

45. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis McCurdy BR Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McCurdy BR. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 12(10). 2012 Authors' objectives The objective of this analysis was to compare hospital-at-home care with inpatient hospital care for patients with acute

Health Technology Assessment (HTA) Database.2012

46. Antibiotic Prevention of Acute Exacerbations of COPD.

Antibiotic Prevention of Acute Exacerbations of COPD. Antibiotic prevention of acute exacerbations of COPD. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22830464 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jul 26;367(4):340-7. doi: 10.1056/NEJMct1115170. Antibiotic prevention of acute exacerbations of COPD. 1 , , . 1 Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, USA. rwenzel@mcvh-vcu.edu Comment in [N Engl J Med. 2012] [N Engl J Med. 2012] [N Engl J Med. 2012] [N Engl J Med. 2012

NEJM2012

47. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD

Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD 21896712 2012 01 23 2012 03 21 2012 01 23 1468-3296 67 2 2012 Feb Thorax Thorax Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. 117-21 10.1136/thoraxjnl-2011-200332 Rates of mortality and readmission are high in patients hospitalised with acute exacerbations (...) of chronic obstructive pulmonary disease (AECOPD). In this population, the prognostic value of the Medical Research Council Dyspnoea Scale (MRCD) is uncertain, and an extended MRCD (eMRCD) scale has been proposed to improve its utility. Coexistent pneumonia is common and, although the CURB-65 prediction tool is used, its discriminatory value has not been reported. Clinical and demographic data were collected on consecutive patients hospitalised with AECOPD. The relationship of stable-state dyspnoea severity to in-hospital mortality

EvidenceUpdates2012

48. Validation of a novel risk score for severity of illness in acute exacerbations of COPD

Validation of a novel risk score for severity of illness in acute exacerbations of COPD 21527510 2011 11 02 2011 12 29 2011 11 02 1931-3543 140 5 2011 Nov Chest Chest Validation of a novel risk score for severity of illness in acute exacerbations of COPD. 1177-83 10.1378/chest.10-3035 Clinicians lack a validated tool for risk stratification in acute exacerbations of COPD (AECOPD). We sought to validate the BAP-65 (elevated BUN, altered mental status, pulse > 109 beats/min, age > 65 years) score

EvidenceUpdates2012

49. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis

Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis Wang J, Nie B, Xiong W, Xu Y CRD summary This well-conducted review found that long-acting beta-agonists reduced the frequency of moderate and severe exacerbations in patients with stable (...) chronic obstructive pulmonary disease (COPD). Salmeterol, formoterol and indacaterol each significantly reduced COPD exacerbations compared with placebo. The results are likely to be reliable, but the conclusions on severe exacerbations should be considered tentative given potential publication bias. Authors' objectives To evaluate the effect of long-acting beta-agonists on the frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Searching MEDLINE, EMBASE, CINAHL and Cochrane Central Register

DARE.2012

50. Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD

Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD 21030489 2011 06 09 2011 09 22 2016 11 25 1931-3543 139 6 2011 Jun Chest Chest Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. 1410-8 10.1378/chest.10-1747 Antibiotic overuse in respiratory illness is common and is associated with drug resistance and hospital-acquired (...) infection. Biomarkers that can identify bacterial infections may reduce antibiotic prescription. We aimed to compare the usefulness of the biomarkers procalcitonin and C-reactive protein (CRP) in patients with pneumonia or exacerbations of asthma or COPD. Patients with a diagnosis of community-acquired pneumonia or exacerbation of asthma or COPD were recruited during the winter months of 2006 to 2008. Demographics, clinical data, and blood samples were collected. Procalcitonin and CRP concentrations

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

51. Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD

Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD BestBets: Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD Report By: Dr Peter Hulme - SHO Search checked by Craig Ferguson - SpR Institution: Trafford General Hospital Date Submitted: 21st June 2008 Date Completed: 3rd May 2011 Last Modified: 3rd June 2011 Status: Green (...) (complete) Three Part Question In [patients with an acute exacerbation of COPD] are [intravenous or oral steroids] better at [reducing length of hospital admission and mortality] Clinical Scenario A 73yr old man with COPD is seen in the Emergency Department. You give him salbutamol and atrovent nebulisers but he remains breathless. You wonder whether giving intravenous or oral steroids would reduce length of hospital stay and his risk of death. Search Strategy EMBASE from 1980 to 2011 Week 08, Ovid

BestBETS2011

52. Impact of care pathways for in-hospital management of COPD exacerbation: a systematic review

Impact of care pathways for in-hospital management of COPD exacerbation: a systematic review Impact of care pathways for in-hospital management of COPD exacerbation: a systematic review Impact of care pathways for in-hospital management of COPD exacerbation: a systematic review Lodewijckx C, Sermeus W, Panella M, Deneckere S, Leigheb F, Decramer M, Vanhaecht K CRD summary The authors concluded that based on the limited available research, accurate conclusions on the impact (...) of chronic obstructive pulmonary disease care pathways could not be drawn. This reflects the evidence presented and, despite some potential limitations in the review process, these conclusions are likely to be reliable. Authors' objectives To evaluate the impact of care pathways for in-hospital management of chronic obstructive pulmonary disease (COPD) exacerbation. Searching MEDLINE, CINAHL, EMBASE and The Cochrane Library and Google were searched from 1990 to May 2010; search terms were reported. Reference lists of selected

DARE.2011

53. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD. 21428765 2011 03 24 2011 04 04 2015 11 19 1533-4406 364 12 2011 Mar 24 The New England journal of medicine N. Engl. J. Med. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. 1093-1103 10.1056/NEJMoa1008378 Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe (...) chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β(2)-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the β(2)-agonist salmeterol in preventing exacerbations of COPD. In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations

NEJM2011

54. Azithromycin for prevention of exacerbations of COPD.

Azithromycin for prevention of exacerbations of COPD. 21864166 2011 08 25 2011 08 30 2016 12 15 1533-4406 365 8 2011 Aug 25 The New England journal of medicine N. Engl. J. Med. Azithromycin for prevention of exacerbations of COPD. 689-98 10.1056/NEJMoa1104623 Acute exacerbations adversely affect patients with chronic obstructive pulmonary disease (COPD). Macrolide antibiotics benefit patients with a variety of inflammatory airway diseases. We performed a randomized trial to determine whether (...) azithromycin decreased the frequency of exacerbations in participants with COPD who had an increased risk of exacerbations but no hearing impairment, resting tachycardia, or apparent risk of prolongation of the corrected QT interval. A total of 1577 subjects were screened; 1142 (72%) were randomly assigned to receive azithromycin, at a dose of 250 mg daily (570 participants), or placebo (572 participants) for 1 year in addition to their usual care. The rate of 1-year follow-up was 89% in the azithromycin

NEJM2011 Full Text: Link to full Text with Trip Pro

55. Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD?

Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? BestBets: Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? Report By: Sandeep Rahul Kusre - Senior House Officer Search checked by Jonathan Costello - Consultant A&E Institution: Royal Free Hospital Date Submitted: 4th April 2009 Date Completed: 21st October 2010 Last Modified: 21st October 2010 Status: Green (...) (complete) Three Part Question In [patients admitted with acute exacerbations of COPD] is [5mg nebulised salbutamol superior to 2.5mg nebulised salbutamol] at [improving lung function and reducing length of hospital stay] Clinical Scenario While working a busy nightshift in A&E, you see a patient with an acute exacerbation of COPD. They require bronchodilators & the nurse asks you if you want 2.5mg or 5mg of nebulised salbutamol. You usually administer 5mg however wondered if 2.5mg salbutamol would have

BestBETS2010

56. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD

Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD 19952063 2010 04 07 2010 04 29 2014 07 30 1931-3543 137 4 2010 Apr Chest Chest Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. 805-11 10.1378/chest.09-1382 Acute exacerbations of COPD reflect in part an inappropriate host response to abnormal bacterial colonization. Orally administered (...) inactivated nontypeable Haemophilus influenzae (NTHi) can drive a specific T-cell response that by promoting intrabronchial phagocytosis down-regulates bronchus inflammation. Subjects with recurrent exacerbations of COPD were studied in a randomized, multicenter, double-blind, placebo-controlled trial, to test efficacy of an NTHi oral immunotherapeutic (HI-164OV). This report describes the outcome in 38 subjects with severe COPD defined as having an FEV(1) < or = 50% of predicted normal. Exacerbations

EvidenceUpdates2010

57. (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study

(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study 19736179 2009 10 29 2010 03 26 2013 11 21 1468-3296 64 11 2009 Nov Thorax Thorax (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. 956-62 10.1136/thx.2008.112243 Chronic obstructive pulmonary disease (COPD) is a chronic disease with a high prevalence and rapidly increasing incidence (...) rates. The effect of self-treatment of COPD exacerbations on the severity of exacerbations during a 1-year period was examined and a cost-effectiveness analysis was performed. Patients were randomly allocated to four 2-hour self-management sessions, with or without training in self-treatment of exacerbations. Patients in the self-treatment group received an action plan with the possibility to initiate a course of prednisolone (with or without antibiotics). During follow-up, all participants kept

EvidenceUpdates2010

58. Systematic review: Combination therapy with long-acting ?-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adver

Systematic review: Combination therapy with long-acting ?-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adver Combination therapy with long-acting β-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adverse (...) Combination therapy with long-acting β-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adverse effects Article Text Therapeutics Systematic review Combination therapy with long-acting β-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated

Evidence-Based Medicine (Requires free registration)2010

59. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis

Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis Van den Bruel A, Gailly J, Neyt M CRD summary The authors concluded that tiotropium reduced the number of exacerbations and hospitalisations (...) of chronic obstructive pulmonary disease (COPD) patients compared with placebo and ipratropium; compared with salmeterol, only the exacerbation frequency was reduced. Given the variability across trials, the possibility of inappropriate pooling and the poor quality of the evidence base, the authors’ conclusions should be interpreted with caution. Authors' objectives To estimate the effect of tiotropium (a long-acting anticholinergic inhalant) on exacerbation and chronic obstructive pulmonary disease (COPD)-related hospitalisation

DARE.2010

60. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials

Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials Agarwal R, Aggarwal AN, Gupta D, Jindal SK CRD summary The review found (...) a modest reduction in risk of exacerbations in patients with severe to very severe chronic obstructive pulmonary disease with use of inhaled corticosteroids that was not related to the level of baseline lung function. The authors suggested that the role of inhaled corticosteroids needed to be further evaluated. Their cautious conclusions are appropriate and reliable. Authors' objectives To assess the efficacy of inhaled corticosteroids in reducing chronic obstructive pulmonary disease (COPD

DARE.2010